CytomX/$CTMX
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About CytomX
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Ticker
$CTMX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
120
ISIN
US23284F1057
Website
CytomX Metrics
BasicAdvanced
$332M
4.35
$0.49
1.11
-
Price and volume
Market cap
$332M
Beta
1.11
52-week high
$3.10
52-week low
$0.40
Average daily volume
8.5M
Financial strength
Current ratio
1.726
Quick ratio
1.63
Long term debt to equity
11.402
Total debt to equity
32.532
Profitability
EBITDA (TTM)
37.645
Gross margin (TTM)
100.00%
Net profit margin (TTM)
28.19%
Operating margin (TTM)
24.37%
Effective tax rate (TTM)
0.57%
Revenue per employee (TTM)
$1,230,000
Management effectiveness
Return on assets (TTM)
15.87%
Return on equity (TTM)
-1,254.80%
Valuation
Price to earnings (TTM)
4.347
Price to revenue (TTM)
1.226
Price to book
6.79
Price to tangible book (TTM)
7.22
Price to free cash flow (TTM)
-2.218
Free cash flow yield (TTM)
-45.09%
Free cash flow per share (TTM)
-95.14%
Growth
Revenue change (TTM)
23.81%
Earnings per share change (TTM)
128.27%
3-year revenue growth (CAGR)
69.35%
10-year revenue growth (CAGR)
37.33%
3-year earnings per share growth (CAGR)
-37.91%
10-year earnings per share growth (CAGR)
-32.49%
What the Analysts think about CytomX
Analyst ratings (Buy, Hold, Sell) for CytomX stock.
Bulls say / Bears say
CytomX reported a 36% increase in revenue to $138.1 million in 2024, driven by collaborations with major pharmaceutical companies like Bristol Myers Squibb and Moderna, indicating strong partnership traction. (CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update)
The company achieved a net income of $31.9 million in 2024, a significant turnaround from a net loss in the previous year, reflecting improved financial health. (CytomX Therapeutics Inc. (CTMX) reports earnings)
CytomX's restructuring in January 2025, including a 40% workforce reduction, is expected to extend its cash runway into Q2 2026, enhancing financial stability. (CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update)
The discontinuation of the CX-904 program with Amgen raises concerns about the viability of CytomX's pipeline and potential future revenue streams. (CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update)
Despite increased revenue, CytomX's cash and investments decreased from $174.5 million in 2023 to $100.6 million in 2024, indicating higher cash burn. (CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update)
The company's reliance on milestone payments from collaborations, without any commercial product sales, makes its revenue stream potentially volatile. (CytomX Therapeutics Inc. (CTMX) reports earnings)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
CytomX Financial Performance
Revenues and expenses
CytomX Earnings Performance
Company profitability
CytomX News
AllArticlesVideos
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewsWire·4 weeks ago
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
GlobeNewsWire·1 month ago
Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report
Benzinga·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for CytomX stock?
CytomX (CTMX) has a market cap of $332M as of June 20, 2025.
What is the P/E ratio for CytomX stock?
The price to earnings (P/E) ratio for CytomX (CTMX) stock is 4.35 as of June 20, 2025.
Does CytomX stock pay dividends?
No, CytomX (CTMX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next CytomX dividend payment date?
CytomX (CTMX) stock does not pay dividends to its shareholders.
What is the beta indicator for CytomX?
CytomX (CTMX) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
